Sep 28, 2023 / 04:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Conference Call and Webcast subject to FDA's approval of Pombiliti + Opfolda. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin, sir.
Andrew Faughnan - Amicus Therapeutics, Inc. - Senior Director of IR
Good morning. Thank you, operator, and thank you, everyone, for joining our conference call to discuss the U.S. FDA approval of Pombiliti and Opfolda. Today's call will be led by Bradley Campbell, President and Chief Executive Officer; and he'll be joined by Dr. Jeff Castelli, Chief Development Officer; and Mike Keavany, President of U.S. Commercial Business and Head of Global Marketing. Available for Q&A is Simon Harford, Chief Financial Officer; and Sébastien Martel, Chief Business Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation
Amicus Therapeutics Inc to Discuss the FDA Approval Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers